• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[简化综合老年评估系统在老年弥漫性大B细胞淋巴瘤患者中的多中心回顾性临床研究]

[A multicenter retrospective clinical study of a simplified comprehensive geriatric assessment system in elderly patients with diffuse large B-cell lymphoma].

作者信息

Leng J Y, Cai Y H, Ge X P, Zhao N P, Su Q Q, Jia Z X, Qian J, Li B Z, Hua H Y, Lu X Z, Zhu H Y, Li J Y, Shi W Y

机构信息

Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Department of Oncology, Affiliated Hospital of Nantong University, Nantong 226001, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):126-133. doi: 10.3760/cma.j.cn121090-20241121-00467.

DOI:10.3760/cma.j.cn121090-20241121-00467
PMID:40134194
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11951222/
Abstract

To evaluate the predictive value of simplified geriatric assessment (sGA) in elderly Chinese patients diagnosed with diffuse large B-cell lymphoma (DLBCL) . It retrospectively analyzed the relationships of sGA with the clinical characteristics, outcome, and prognosis of 219 patients aged ≥60 years who were newly diagnosed with DLBCL at six hospitals in Jiangsu province between January 2018 and December 2022. The median age of 219 patients was 68 years (60-87 years). According to the sGA system criteria, 101 (46.1%), 103 (47.0%), and 15 (6.8%) elderly patients with DLBCL were categorized as fit, unfit, and frail, respectively. The most common adverse reactions after chemotherapy were hematologic, and the incidence of grade >2 hematologic adverse reactions was similar among the three groups (47.5% 41.7% 46.7%, respectively; (2)=0.712, =0.700). Compared with the fit and unfit groups, the frail group showed tendencies toward for higher proportions of grade >2 gastrointestinal, pulmonary, and infectious adverse reactions (>0.05 for all). The fit, unfit, and frail groups had respective remission rates of 74.3%, 46.6%, and 20.0% ((2)=25.249, <0.001) ; disease progression rates of 5.9%, 11.7%, and 26.7% ((2)=6.763, <0.05) ; 2-year overall survival rates of 92.1% (95% 86.6% to 97.9%), 77.6% (95% 69.5% to 86.6%), and 70.1% (95% 49.4% to 99.6%) (<0.05) ; and 2-year progression-free survival rates of 76.8% (95% 67.0% to 84.8%), 69.7% (95% 61.8% to 82.0%), and 65.7% (95% 53.3% to 100%) (=0.399) . sGA can effectively predict treatment adverse effects and efficacy, disease progression, and long-term survival in elderly DLBCL.

摘要

评估简化老年综合评估(sGA)对中国老年弥漫性大B细胞淋巴瘤(DLBCL)患者的预测价值。回顾性分析2018年1月至2022年12月期间江苏省六家医院新诊断为DLBCL的219例年龄≥60岁患者的sGA与临床特征、结局及预后的关系。219例患者的中位年龄为68岁(60 - 87岁)。根据sGA系统标准,101例(46.1%)、103例(47.0%)和15例(6.8%)老年DLBCL患者分别被归类为适合、不适合和虚弱。化疗后最常见的不良反应是血液学不良反应,三组中>2级血液学不良反应的发生率相似(分别为47.5%、41.7%、46.7%;(2)=0.712,=0.700)。与适合和不适合组相比,虚弱组>2级胃肠道、肺部和感染性不良反应的比例有升高趋势(均P>0.05)。适合、不适合和虚弱组的缓解率分别为74.3%、46.6%和20.0%((2)=25.249,P<0.001);疾病进展率分别为5.9%、11.7%和26.7%((2)=6.763,P<0.05);2年总生存率分别为92.1%(95%CI 86.6%至97.9%)、77.6%(95%CI 69.5%至86.6%)和70.1%(95%CI 49.4%至99.6%)(P<0.05);2年无进展生存率分别为76.8%(95%CI 67.0%至84.8%)、69.7%(95%CI 61.8%至82.0%)和65.7%(95%CI 53.3%至100%)(P=0.399)。sGA可有效预测老年DLBCL患者的治疗不良反应和疗效、疾病进展及长期生存情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ce1/11951222/a9da069482c2/cjh-46-02-126-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ce1/11951222/04764c44e465/cjh-46-02-126-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ce1/11951222/a9da069482c2/cjh-46-02-126-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ce1/11951222/04764c44e465/cjh-46-02-126-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ce1/11951222/a9da069482c2/cjh-46-02-126-g002.jpg

相似文献

1
[A multicenter retrospective clinical study of a simplified comprehensive geriatric assessment system in elderly patients with diffuse large B-cell lymphoma].[简化综合老年评估系统在老年弥漫性大B细胞淋巴瘤患者中的多中心回顾性临床研究]
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):126-133. doi: 10.3760/cma.j.cn121090-20241121-00467.
2
Treating newly diagnosed Diffuse Large B-cell Lymphoma in the elderly patient with R-mini-CHOP: A single centre analytical retrospective observational study.用R-mini-CHOP方案治疗老年新诊断弥漫性大B细胞淋巴瘤:一项单中心分析性回顾性观察研究。
Med J Malaysia. 2025 May;80(3):307-312.
3
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
4
HALP score and GNRI: Simple and powerful prognostic markers in diffuse large B-cell lymphoma.HALP评分与GNRI:弥漫性大B细胞淋巴瘤中简单而有效的预后标志物。
Medicine (Baltimore). 2025 May 30;104(22):e42165. doi: 10.1097/MD.0000000000042165.
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
6
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.老年新诊断胶质母细胞瘤的治疗:一项网状Meta分析
Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261. doi: 10.1002/14651858.CD013261.pub2.
7
The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China.ZR2与类R-CHOP方案治疗新诊断老年弥漫性大B细胞淋巴瘤的疗效及安全性:中国一项单中心前瞻性研究
Ann Hematol. 2025 Jan;104(1):605-615. doi: 10.1007/s00277-024-06066-3. Epub 2024 Oct 30.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
10
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.

本文引用的文献

1
Curative intent therapy for DLBCL in the elderly.老年弥漫性大 B 细胞淋巴瘤的治愈性意图治疗。
Leuk Lymphoma. 2024 May;65(5):560-569. doi: 10.1080/10428194.2024.2302323. Epub 2024 Jan 11.
2
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.伊布替尼、利妥昔单抗和来那度胺用于 75 岁或以上初治弥漫性大 B 细胞淋巴瘤不适合或虚弱患者:一项 2 期、单臂研究。
Lancet Healthy Longev. 2022 Jul;3(7):e481-e490. doi: 10.1016/S2666-7568(22)00123-4.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
4
Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma.老年 8 项与老年弥漫性大 B 细胞淋巴瘤患者治疗强度和预后的关系。
Br J Haematol. 2021 Jul;194(2):325-335. doi: 10.1111/bjh.17554. Epub 2021 May 26.
5
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi.简化版老年综合评估在弥漫大 B 细胞淋巴瘤老年患者中的应用:意大利淋巴瘤基金会的前瞻性老年项目。
J Clin Oncol. 2021 Apr 10;39(11):1214-1222. doi: 10.1200/JCO.20.02465. Epub 2021 Feb 12.
6
Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.全面老年评估(CGA):指导中国老年弥漫大 B 细胞淋巴瘤患者治疗的简单工具。
Oncologist. 2020 Aug;25(8):e1202-e1208. doi: 10.1634/theoncologist.2019-0738. Epub 2020 Jun 11.
7
Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma.老年营养风险指数联合合并症指数对老年弥漫性大 B 细胞淋巴瘤患者预后的预测价值。
Br J Haematol. 2021 Jan;192(1):100-109. doi: 10.1111/bjh.16743. Epub 2020 May 14.
8
Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.血液系统恶性肿瘤老年患者的步态速度、握力和临床结局。
Blood. 2019 Jul 25;134(4):374-382. doi: 10.1182/blood.2019000758. Epub 2019 Jun 5.
9
Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.吉西他滨-奥沙利铂联合利妥昔单抗(R-GemOx)作为老年弥漫性大B细胞淋巴瘤患者的一线治疗:一项单臂、开放标签的2期试验。
Lancet Haematol. 2018 Jun;5(6):e261-e269. doi: 10.1016/S2352-3026(18)30054-1. Epub 2018 May 8.
10
Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).综合老年评估是支持老年弥漫性大B细胞淋巴瘤患者治疗决策的重要工具:意大利淋巴瘤基金会(FIL)对173例患者进行的前瞻性多中心评估。
Leuk Lymphoma. 2015 Apr;56(4):921-6. doi: 10.3109/10428194.2014.953142. Epub 2014 Oct 9.